Epidemiology and pathophysiology of malignancy in common variable immunodeficiency?

被引：39

作者：

Manesh, A. Tak ^{[1
]}

Azizi, G. ^{[2
,3
]}

Heydari, A. ^{[3
]}

Kiaee, F. ^{[3
]}

Shaghaghi, M. ^{[3
]}

Hossein-Khannazer, N. ^{[4
]}

Yazdani, R. ^{[5
]}

Abolhassani, H. ^{[3
,6
]}

Aghamohammadi, A. ^{[3
]}

机构：

[1] RACGP, Melbourne, Vic, Australia

[2] Alborz Univ Med Sci, Imam Hassan Mojtaba Hosp, Dept Lab Med, Karaj, Iran

[3] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Tehran, Iran

[4] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[5] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran

[6] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden

来源：

ALLERGOLOGIA ET IMMUNOPATHOLOGIA | 2017年 / 45卷 / 06期

关键词：

Common variable immunodeficiency; Malignancy; Cancer; Lymphoma; NON-HODGKIN-LYMPHOMA; EPSTEIN-BARR-VIRUS; HELICOBACTER-PYLORI; GASTRIC-CANCER; CHROMOSOMAL RADIOSENSITIVITY; ANTIBODY DEFICIENCY; PEDIATRIC-PATIENTS; IMMUNE-DEFICIENCY; IGA DEFICIENCY; MALT LYMPHOMA;

D O I：

10.1016/j.aller.2017.01.006

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Common variable immunodeficiency (CVID) is a diagnostic category of primary immunodeficiency (PID) which may present with heterogeneous disorders including recurrent infections, autoimmunity, granulomatous diseases, lymphoid and other types of malignancies. Generally, the incidence of malignancy in CVID patients is around 1.5-20.7% and usually occurs during the 4th-6th decade of life. Non-Hodgkin lymphoma is the most frequent malignancy, followed by epithelial tumours of stomach, breast, bladder and cervix. The exact pathological mechanisms for cancer development in CVID are not fully determined; however, several mechanisms including impaired genetic stability, genetic predisposition, immune dysreguladon, impaired clearance of oncogenic viruses and bacterial infections, and iatrogenic causes have been proposed to contribute to the high susceptibility of these patients to malignancies. (C) 2017 Published by Elsevier Espana, S.L.U. on behalf of SEICAP.

引用

页码：602 / 615

页数：14

共 167 条

[21]

Azizi G., 2016, EXPERT REV CLIN IMMU, V28, P1

[22]

Azizi G., 2016, CELL IMMUNOL

[23]

Azizi G., 2016, SCAND J IMMUNOL

[24]

Azizi G, 2016, EXPERT REV CLIN IMMU, V16, P1